Lorey K Smith

Inhibition of pyrimidine biosynthesis targets protein translation in acute myeloid leukemia

Joan So, Alexander C Lewis, Lorey K Smith, Kym Stanley, Rheana Franich, David Yoannidis, Lizzy Pijpers, Pilar Dominguez, Simon J Hogg, Stephin J Vervoort, Fiona C Brown, Ricky W Johnstone, Gabrielle McDonald, Danielle B Ulanet, Josh Murtie, Emily Gruber, Lev M Kats

Journal article  |  2022  |  EMBO MOLECULAR MEDICINE

The mitochondrial enzyme dihydroorotate dehydrogenase (DHODH) catalyzes one of the rate-limiting steps in de novo pyrimidine biosy..

Pharmacologic Reduction of Mitochondrial Iron Triggers a Noncanonical BAX/BAK Dependent Cell Death

Sylvain Garciaz, Andrew A Guirguis, Sebastian Muller, Fiona C Brown, Yih-Chih Chan, Ali Motazediani, Caitlin L Rowe, James A Kuzich, Kah Lok Chan, Kevin Tran, Lorey Smith, Laura MacPherson, Brian Liddicoat, Enid YN Lam, Tatiana Caneque, Marian L Burr, Veronique Litalien, Giovanna Pomilio, Mathilde Poplineau, Estelle Duprez, et al.

Journal article  |  2022  |  CANCER DISCOVERY

UNLABELLED: Cancer cell metabolism is increasingly recognized as providing an exciting therapeutic opportunity. However, a drug th..

Adaptive translational reprogramming of metabolism limits the response to targeted therapy in BRAF(V600) melanoma

Lorey K Smith, Tiffany Parmenter, Margarete Kleinschmidt, Eric P Kusnadi, Jian Kang, Claire A Martin, Peter Lau, Riyaben Patel, Julie Lorent, David Papadopoli, Anna Trigos, Teresa Ward, Aparna D Rao, Emily J Lelliott, Karen E Sheppard, David Goode, Rodney J Hicks, Tony Tiganis, Kaylene J Simpson, Ola Larsson, et al.

Journal article  |  2022  |  NATURE COMMUNICATIONS

Despite the success of therapies targeting oncogenes in cancer, clinical outcomes are limited by residual disease that ultimately ..

Enhancing Adoptive Cell Transfer with Combination BRAF-MEK and CDK4/6 Inhibitors in Melanoma

Peter Kar Han Lau, Carleen Cullinane, Susan Jackson, Rachael Walker, Lorey K Smith, Alison Slater, Laura Kirby, Riyaben P Patel, Bianca von Scheidt, Clare Y Slaney, Grant A McArthur, Karen E Sheppard

Journal article  |  2021  |  CANCERS

Despite the success of immune checkpoint inhibitors that target cytotoxic lymphocyte antigen-4 (CTLA-4) and programmed-cell-death-..

Phenotypic Consequences of SLC25A40-ABCB1 Fusions beyond Drug Resistance in High-Grade Serous Ovarian Cancer

Kathleen Pishas, Karla J Cowley, Ahwan Pandey, Therese Hoang, Jessica A Beach, Jennii Luu, Robert Vary, Lorey K Smith, Carolyn E Shembrey, Nineveh Rashoo, Madelynne O White, Kaylene J Simpson, Andrea Bild, Jason Griffiths, Dane Cheasley, Ian Campbell, David DL Bowtell, Elizabeth L Christie

Journal article  |  2021  |  CANCERS

Despite high response rates to initial chemotherapy, the majority of women diagnosed with High-Grade Serous Ovarian Cancer (HGSOC)..

Metabolic Plasticity in Melanoma Progression and Response to Oncogene Targeted Therapies

Arwa Alkaraki, Grant A McArthur, Karen E Sheppard, Lorey K Smith

Journal article  |  2021  |  CANCERS

Resistance to therapy continues to be a barrier to curative treatments in melanoma. Recent insights from the clinic and experiment..

Melanoma brain metastases that progress on BRAF-MEK inhibitors demonstrate resistance to ipilimumab-nivolumab that is associated with the Innate PD-1 Resistance Signature (IPRES)

Peter Kar Han Lau, Breon Feran, Lorey Smith, Arian Lasocki, Ramyar Molania, Kortnye Smith, Alison Weppler, Christopher Angel, Damien Kee, Prachi Bhave, Belinda Lee, Richard J Young, Amir Iravani, Hanxian Aw Yeang, Ismael A Vergara, David Kok, Kate Drummond, Paul Joseph Neeson, Karen E Sheppard, Tony Papenfuss, et al.

Journal article  |  2021  |  JOURNAL FOR IMMUNOTHERAPY OF CANCER

BACKGROUND: Melanoma brain metastases (MBMs) are a challenging clinical problem with high morbidity and mortality. Although first-..

Is resistance to targeted therapy in cancer inevitable?

Lorey K Smith, Karen E Sheppard, Grant A McArthur

Journal article  |  2021  |  CANCER CELL

Resistance to targeted therapies is a major challenge in cancer care and occurs via genetic and non-genetic mechanisms. In this is..

CDK4/6 Inhibition Reprograms Mitochondrial Metabolism in BRAF(V600) Melanoma via a p53 Dependent Pathway

Nancy T Santiappillai, Shatha Abuhammad, Alison Slater, Laura Kirby, Grant A McArthur, Karen E Sheppard, Lorey K Smith

Journal article  |  2021  |  CANCERS

Cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors are being tested in numerous clinical trials and are currently employed succes..

Genome-wide RNAi screen for genes regulating glycolytic response to vemurafenib in BRAF(V600) melanoma cells

Lorey K Smith, Tiffany Parmenter, Cathryn M Gould, Piyush B Madhamshettiwar, Karen E Sheppard, Kaylene J Simpson, Grant A McArthur

Journal article  |  2020  |  SCIENTIFIC DATA

Identification of mechanisms underlying sensitivity and response to targeted therapies, such as the BRAF inhibitor vemurafenib, is..